Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD19-PD-1/CD28-CAR T cells |
Synonyms | |
Therapy Description |
CD19-PD-1/CD28-CAR T cells consist of autologous T-lymphomcytes engineered to produce a chimeric antigen receptor (CAR) with an anti-CD19 fragment and a PD-1/CD28 chimeric switch-receptor, which may lead to potential cytotoxic activity against tumor cells expressing PD-L1 (PMID: 33028589). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD19-PD-1/CD28-CAR T cells | CD19-PD-1/CD28-CAR T cells consist of autologous T-lymphomcytes engineered to produce a chimeric antigen receptor (CAR) with an anti-CD19 fragment and a PD-1/CD28 chimeric switch-receptor, which may lead to potential cytotoxic activity against tumor cells expressing PD-L1 (PMID: 33028589). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | B-cell lymphoma | sensitive | CD19-PD-1/CD28-CAR T cells | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CD19-PD-1/CD28 CAR T cell treatment induced dose-dependent cytotoxicity against a B cell lymphoma cell line with CD274 overexpression in culture, and resulted in greater inhibition of tumor growth in a cell line xenograft model compared to treatment with anti-CD19 CAR T cells alone or combined with an anti-PD-1 antibody (PMID: 33028589). | 33028589 |
CD274 positive | diffuse large B-cell lymphoma | predicted - sensitive | CD19-PD-1/CD28-CAR T cells | Case Reports/Case Series | Actionable | In a Phase Ib trial, CD19-PD-1/CD28-CAR T cell treatment in two patients with CD274 positive diffuse large B-cell lymphoma resulted in complete remission (CR) after 3 months, however, disease progression was observed in one patient after 2 months, while the other patient achieved persistent CR. (PMID: 33028589). | 33028589 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|